Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg vs Olmesartan Medoxomil 40 mg in Essential Hypertension
2006-005556-32Phase 3Completed
- Sponsor
- Menarini Group
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing Olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg with Olmesartan medoxomil 40 mg (2 arms). Primary endpoints: Change in mean trough sitting diastolic blood pressure at 8 weeks and Change in mean trough sitting systolic blood pressure at 8 weeks. Started Apr 2007; status: completed.
02
Drugs
olmesartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2006-005556-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005556-32.